-Primo N Lara Researcher Activity Profile

Research Author Detailed Information 

Primo N Lara Publication Rate By Year

Primo N Lara has published 2 paper(s) in 2006, 19 paper(s) in 2007, 12 paper(s) in 2008, for a total of 33 research publications in total.

Primo N Pn Lara Author Information

LAST NAME: lara

FIRST NAME: Primo N

INITIALS: pn

AFFILIATION:

Papers

Primo N Lara's Publication Record

1. Bortezomib (PS-341) in relapsed or refractory extensive stage small cell lung cancer: a Southwest Oncology Group phase II trial (S0327). Year Published: 2007
University of California, Davis Cancer Center, Sacramento, CA 95817, USA. primo.lara@ucdmc.ucdavis.edu
2. Long-term survival with concurrent chemoradiation therapy followed by consolidation docetaxel in stage IIIB non-small-cell lung cancer: a phase II Southwest Oncology Group Study (S9504). Year Published: 2006
University of California, Davis Cancer Center, Sacramento, CA 95817, USA. david.gandara@ucdmc.ucdavis.edu
3. Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors. Year Published: 2007
Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA. motzerr@mskcc.org
4. Biologic agents as adjunctive therapy for prostate cancer: a rationale for use with androgen deprivation. Year Published: 2007
University of California, Davis, CA, USA.
5. Clinical implications of neuroendocrine differentiation in prostate cancer. Year Published: 2007
Department of Urology, Davis Medical Center, University of California at Davis, Sacramento, CA 95817, USA.
6. Renal cell carcinoma: current status and emerging therapies. Year Published: 2007
Department of Urology, University of California, Davis Medical Center, Sacramento, CA 95817, USA. enelson06m@gmail.com
7. Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute trial. Year Published: 2007
University of Michigan, Ann Arbor, USA. mahahuss@umich.edu
8. Sorafenib with interferon alfa-2b as first-line treatment of advanced renal carcinoma: a phase II study of the Southwest Oncology Group. Year Published: 2007
Oregon Health and Science University, Portland, OR, USA.
9. Phase II clinical trial of the epothilone B analog, ixabepilone, in patients with non small-cell lung cancer whose tumors have failed first-line platinum-based chemotherapy. Year Published: 2007
Respiratory Oncology Unit, University Hospital Gasthuisberg, Leuven, Belgium. johan.vansteenkiste@uz.kuleuven.ac.be
10. Prostate cancer and markers of bone metabolism: diagnostic, prognostic, and therapeutic implications. Year Published: 2007
Department of Urology, University of California, Davis Medical Center, 4860 Y St, Suite 3500, Sacramento, CA 95817, USA. enelson06m@gmail.com
11. Inhibition of Akt pathways in the treatment of prostate cancer. Year Published: 2007
1Department of Urology, University of California at Davis, Sacramento, CA, USA.
12. Combination treatment of prostate cancer cell lines with bioactive soy isoflavones and perifosine causes increased growth arrest and/or apoptosis. Year Published: 2007
Department of Urology, University of California, Davis, School of Medicine and Cancer Center, Sacramento, California 95817, USA.
13. Small-cell carcinoma of the urinary bladder: diagnosis and management. Year Published: 2006
University of California at Davis, Department of Internal Medicine, Division of Hematology/Oncology, Department of Urology, 4501 X Street, Room 3016, Sacramento, CA 95817, USA. cxpan@ucdavis.edu
14. Prostate cancer and markers of bone metabolism: diagnostic, prognostic, and therapeutic implications. Year Published: 2007
Department of Urology, University of California, Davis Medical Center, 4860 Y St, Suite 3500, Sacramento, CA 95817, USA. enelson06m@gmail.com
15. Phase I study of two different schedules of bortezomib and pemetrexed in advanced solid tumors with emphasis on non-small cell lung cancer. Year Published: 2007
University of California, Davis Cancer Center, Sacramento, California 95817, USA. angela.davies@ucdmc.ucdavis.edu
16. Overcoming barriers to cancer clinical trial accrual: impact of a mass media campaign. Year Published: 2007
University of California Davis Cancer Center, Sacramento, California.
17. Combination treatment of prostate cancer cell lines with bioactive soy isoflavones and perifosine causes increased growth arrest and/or apoptosis. Year Published: 2007
Department of Urology, University of California, Davis, School of Medicine and Cancer Center, Sacramento, California 95817, USA.
18. The proteasome inhibitor bortezomib in combination with gemcitabine and carboplatin in advanced non-small cell lung cancer: a California Cancer Consortium Phase I study. Year Published: 2008
Division of Hematology and Oncology, Davis Cancer Center, University of California, Sacramento, California 95817, USA. angela.davies@ucdmc.ucdavis.edu
19. The proteasome inhibitor bortezomib in combination with gemcitabine and carboplatin in advanced non-small cell lung cancer: a California Cancer Consortium Phase I study. Year Published: 2008
Division of Hematology and Oncology, Davis Cancer Center, University of California, Sacramento, California 95817, USA. angela.davies@ucdmc.ucdavis.edu
20. Schedule-Dependent Apoptosis in K-ras Mutant Non-Small-Cell Lung Cancer Cell Lines Treated with Docetaxel and Erlotinib: Rationale for Pharmacodynamic Separation. Year Published: 2008
University of California Davis Cancer Center, Sacramento.
21. The proteasome inhibitor bortezomib in combination with gemcitabine and carboplatin in advanced non-small cell lung cancer: a California Cancer Consortium Phase I study. Year Published: 2008
Division of Hematology and Oncology, Davis Cancer Center, University of California, Sacramento, California 95817, USA. angela.davies@ucdmc.ucdavis.edu
22. Disease control rate at 8 weeks predicts clinical benefit in advanced non-small-cell lung cancer: results from Southwest Oncology Group randomized trials. Year Published: 2008
University of California Davis Cancer Center, 4501 X St, Sacramento, CA 95817, USA. primo.lara@ucdmc.ucdavis.edu
23. Phase I study of two different schedules of bortezomib and pemetrexed in advanced solid tumors with emphasis on non-small cell lung cancer. Year Published: 2007
University of California, Davis Cancer Center, Sacramento, California 95817, USA. angela.davies@ucdmc.ucdavis.edu
24. Schedule-dependent apoptosis in K-ras mutant non-small-cell lung cancer cell lines treated with docetaxel and erlotinib: rationale for pharmacodynamic separation. Year Published: 2008
University of California Davis Cancer Center, Sacramento, CA 95817, USA. angela.davies@ucdmc.ucdavis.edu
25. Overcoming barriers to cancer clinical trial accrual: impact of a mass media campaign. Year Published: 2007
University of California Davis Cancer Center, Sacramento, California 95817, USA.
26. Overcoming barriers to cancer clinical trial accrual: impact of a mass media campaign. Year Published: 2007
University of California Davis Cancer Center, Sacramento, California 95817, USA.
27. Schedule-dependent apoptosis in K-ras mutant non-small-cell lung cancer cell lines treated with docetaxel and erlotinib: rationale for pharmacodynamic separation. Year Published: 2008
University of California Davis Cancer Center, Sacramento, CA 95817, USA. angela.davies@ucdmc.ucdavis.edu
28. Disease control rate at 8 weeks predicts clinical benefit in advanced non-small-cell lung cancer: results from Southwest Oncology Group randomized trials. Year Published: 2008
University of California Davis Cancer Center, 4501 X St, Sacramento, CA 95817, USA. primo.lara@ucdmc.ucdavis.edu
29. The AKT Inhibitor Perifosine in Biochemically Recurrent Prostate Cancer: A Phase II California/Pittsburgh Cancer Consortium Trial. Year Published: 2008
University of California Davis Cancer Center, Sacramento.
30. The AKT inhibitor perifosine in biochemically recurrent prostate cancer: a phase II California/Pittsburgh cancer consortium trial. Year Published: 2008
University of California Davis Cancer Center, Sacramento, CA 95817, USA.
31. Regulation of Id1 expression by SRC: implications for targeting of the bone morphogenetic protein pathway in cancer. Year Published: 2008
Department of Medical Oncology, Bern University Hospital, Bern, Switzerland. oliver.gautschi@insel.ch
32. Thymoma-associated multiorgan autoimmunity: a graft-versus-host-like disease. Year Published: 2007
Permanente Medical Group, Fremont, California, USA.
33. Regulation of Id1 expression by SRC: implications for targeting of the bone morphogenetic protein pathway in cancer. Year Published: 2008
Department of Medical Oncology, Bern University Hospital, Bern, Switzerland. oliver.gautschi@insel.ch